Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 3Ovarian Neoplasms 2Neoplasms 2Uterine Cervical Neoplasms 1Recurrence 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Non-squamous Non-small-cell Lung Cancer 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 6human papillomavirus vaccine, L1 type 16, 18 4Vaccines 3fluciclovine F-18 2pegylated granulocyte colony-stimulating factor 1halofantrine 1ferrous fumarate 1epoetin beta 1apatinib 1Tobacco Use Cessation Devices 1TachoSil 1Surveys and Questionnaires 1Radiotherapy 1Quality of Life 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Patient Navigation 1Papillomavirus Vaccines 1Mindfulness 1Indocyanine Green 1Human Papillomavirus Recombinant Vaccine nonavalent 1Hepatitis B Vaccines 1Gonadal Steroid Hormones 1Gene Expression Profiling 1Engerix-B 1Early Intervention, Educational 1Counseling 1Cognitive Behavioral Therapy 1Cisplatin 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Uterine Cervical Neoplasms × apatinib × Clear all
NCT03384511 2018-02-20

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

Shandong Cancer Hospital and Institute

Phase 4 Completed
38 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡